NIH extends PPD HIV research support contract until 2024

By Melissa Fassbender contact

- Last updated on GMT

NIH extends PPD HIV research support contract until 2024

Related tags: Clinical trial, Health care, Epidemiology

The renewed contract covers a range of research related services, including monitoring therapeutic trials, prevention trials, and vaccines work, with the ultimate goal of an "AIDS-free generation."

Pharmaceutical Product Development, LLC (PPD) has secured a  renewal of its contract with the Division of AIDS (DAIDS​), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the fifth time.

The contracts range from five to seven years and involve monitoring for approximately 150 clinical studies per contract.

The original NIAID/DAIDS contract was awarded 27 years ago, and the latest renewal will extend the clinical trial services relationship until 2024.

Patti McNamara, vice president, government and public health services for PPD, told us the relationship has expanded since 1990.

While the core services have remained the same, the underlying protocols have grown in number, size and complexity as the science has matured​,” explained McNamara.

As part of the relationship, PPD predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors.

Additionally, she said the contract value has more than tripled for the current contract period versus the contract initially awarded in 1990. The CRO is also now monitoring projects at sites throughout the world.

The extension covers site monitoring for HIV treatment and prevention clinical trials. Sites are located around the world with the highest number in the US and Africa​,” said McNamara.

Over the years, we have partnered with DAIDS to support this important organization’s global research efforts to advance the biological knowledge of HIV/AIDS and its related co-infections and co-morbidities, with the ultimate goal of creating an AIDS-free generation​.”

(Feature image: iStock/Jovanmandic)

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars